ABIONYX Pharma Company Description

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.

It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis (NASH).

The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.

ABIONYX Pharma SA was founded in 2005 and is headquartered in Balma, France.

ABIONYX Pharma SA

Country	France
Founded	2005
Industry	Biotechnology
Sector	Healthcare
Employees	51
CEO	Cyrille Tupin

Contact Details

Address: 33 43 avenue Georges Pompidou Building D2 Balma, 31130 France
Phone	33 5 62 24 97 06
Website	abionyx.com

Stock Details

Ticker Symbol	ABNX
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0012616852
SIC Code	2836

Key Executives

Name	Position
Sir Cyrille Tupin CPA	Chief Executive Officer, GM and Director
Prof. Christian Chavy MBA	Independent Director
Emmanuel De Fougeroux	Administrative and Financial Director
Constance Keyserling Peyrottes M.S.	Vice President of Clinical, Regulatory Development and Operations
Dr. Robert Andrew Donald Scott M.D.	Chief Medical Officer and Head of Research & Development
Laurent Guerci	Chief Digital and Innovation Officer